Guardian reiterates 2025 guidance, provides 2026 outlook with ~11% adj. EBITDA growth

Guardian Pharmacy Services, Inc.

Reaffirmed 2025 revenue $1.43B-$1.45B and adjusted EBITDA $104M-$106M.
2026 outlook: revenue $1.40B-$1.42B (down due to IRA drug price cuts) and adjusted EBITDA $115M-$118M.
2026 adjusted EBITDA margin expected above 8%, structural improvement from 2025.
Completed year-end acquisition of a single pharmacy in Montana, adding new territory.
CEO expects low double-digit adjusted EBITDA growth despite mandatory price reductions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.